IgA vasculitis presenting as nephrotic syndrome, a complication of covid-19 vaccination
Written By : Niveditha Subramani
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2023-01-13 03:30 GMT | Update On 2023-01-13 06:28 GMT
Advertisement
A recent study in the BMC Nephrology, by Illeon Cho and team closely warn about the concerns post covid -19 vaccination they state physicians should keep in mind the potential (re)activation of IgA vasculitis following mRNA COVID-19 vaccines and is important to closely monitor COVID-19 vaccinated patients, particularly those with autoimmune diseases.
The global COVID-19 vaccine campaign has been actively underway to overcome the COVID-19 pandemic. Backing up the strong recommendation for coronavirus disease 2019 (COVID 19) vaccination, many patients with medical comorbidities are being immunized. However, the safety of vaccination in patients with autoimmune diseases has not been well established.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.